DECLARE-TIMI 58 Trial in the Context of EMPA-REG OUTCOME and CANVAS

Diabetes Mellitus - Russian Federation
doi 10.14341/dm10289
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Endocrinology Research Centre

Related search

Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2018English

Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2017English

EMPA-REG OUTCOME: The Endocrinologist's Point of View

American Journal of Medicine
Medicine
2017English

EMPA-REG OUTCOME: The Nephrologist's Point of View

American Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

EMPA-REG OUTCOME: The Cardiologist's Point of View

American Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Following the Results of the EMPA-REG OUTCOME Trial With Empagliflozin, Is It Possible to Speak of a Class Effect?

International Journal of General Medicine
Medicine
2017English

Pdb62 - Cost-Effectiveness Analysis of Empagliflozin in Japan Based on Results From the Subgroup Analysis of Asian Patients in the Empa-Reg Outcome Trial

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Consistent Cardiovascular (CV) Benefit of Empagliflozin Over the Spectrum of CV Risk Factor Control in EMPA-REG OUTCOME

Metabolism: Clinical and Experimental
EndocrinologyMetabolismDiabetes
2020English

Comparison of Adipose Distribution Indices With Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy